SA518400696B1 - معدِّلات صغيرة الجزيء لإنزيمات بانتوثينات كيناز - Google Patents

معدِّلات صغيرة الجزيء لإنزيمات بانتوثينات كيناز Download PDF

Info

Publication number
SA518400696B1
SA518400696B1 SA518400696A SA518400696A SA518400696B1 SA 518400696 B1 SA518400696 B1 SA 518400696B1 SA 518400696 A SA518400696 A SA 518400696A SA 518400696 A SA518400696 A SA 518400696A SA 518400696 B1 SA518400696 B1 SA 518400696B1
Authority
SA
Saudi Arabia
Prior art keywords
alkyl
alkoxy
chosen
halogen
compound
Prior art date
Application number
SA518400696A
Other languages
Arabic (ar)
English (en)
Inventor
سوزان جاكوسكى
كارليس او روك
شيترا سوبرامانين
لاليت كومار شارما
ريتشارد اى لى
جيويا ليو
مى كيونج يون
Original Assignee
اس تى . جود شيلدرينز ريسيرش هوسبيتال، انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60783428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA518400696(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by اس تى . جود شيلدرينز ريسيرش هوسبيتال، انك. filed Critical اس تى . جود شيلدرينز ريسيرش هوسبيتال، انك.
Publication of SA518400696B1 publication Critical patent/SA518400696B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SA518400696A 2016-06-23 2018-12-19 معدِّلات صغيرة الجزيء لإنزيمات بانتوثينات كيناز SA518400696B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662354012P 2016-06-23 2016-06-23
PCT/US2017/039037 WO2017223474A1 (en) 2016-06-23 2017-06-23 Small molecule modulators of pantothenate kinases

Publications (1)

Publication Number Publication Date
SA518400696B1 true SA518400696B1 (ar) 2023-01-09

Family

ID=60783428

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400696A SA518400696B1 (ar) 2016-06-23 2018-12-19 معدِّلات صغيرة الجزيء لإنزيمات بانتوثينات كيناز

Country Status (13)

Country Link
US (2) US10899734B2 (enExample)
EP (1) EP3474667A4 (enExample)
JP (1) JP7078555B2 (enExample)
KR (1) KR102459256B1 (enExample)
CN (1) CN109561680B (enExample)
AU (1) AU2017281907B2 (enExample)
DO (1) DOP2018000293A (enExample)
IL (1) IL263649B (enExample)
MX (1) MX383697B (enExample)
SA (1) SA518400696B1 (enExample)
SG (1) SG11201811023UA (enExample)
WO (1) WO2017223474A1 (enExample)
ZA (1) ZA201808099B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899734B2 (en) 2016-06-23 2021-01-26 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
US11891378B2 (en) * 2017-12-27 2024-02-06 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
US11547709B2 (en) 2017-12-27 2023-01-10 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
CA3106470A1 (en) * 2018-07-17 2020-01-23 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
US20220185796A1 (en) * 2019-03-27 2022-06-16 St. Jude Children's Research Hospital Small molecule modulators of pank
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
CA3135344A1 (en) * 2019-03-29 2020-10-08 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP4262814A4 (en) * 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
CN119654314A (zh) * 2022-08-08 2025-03-18 艾捷斯治疗公司 作为jak2抑制剂的杂环酰胺和脲化合物
CN119745886A (zh) * 2025-01-20 2025-04-04 中国药科大学 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
AU2001294547A1 (en) * 2000-09-14 2002-03-26 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
AU2003236500B9 (en) * 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005011653A2 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
AU2008269128B2 (en) 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2012280420B2 (en) 2011-07-01 2017-01-05 Remynd Nv 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
CN104583194A (zh) * 2012-05-11 2015-04-29 艾伯维公司 作为nampt抑制剂的哒嗪和吡啶衍生物
TW201444821A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
CA2982811A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
US10899734B2 (en) 2016-06-23 2021-01-26 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases

Also Published As

Publication number Publication date
DOP2018000293A (es) 2019-04-15
US20210246113A1 (en) 2021-08-12
SG11201811023UA (en) 2019-01-30
CN109561680A (zh) 2019-04-02
RU2019101613A (ru) 2020-07-23
IL263649B (en) 2022-04-01
CN109561680B (zh) 2021-07-13
EP3474667A1 (en) 2019-05-01
EP3474667A4 (en) 2019-11-27
MX2018015170A (es) 2019-07-04
AU2017281907A1 (en) 2019-01-03
KR102459256B1 (ko) 2022-10-25
KR20190022620A (ko) 2019-03-06
US20190300499A1 (en) 2019-10-03
JP2019518764A (ja) 2019-07-04
NZ749147A (en) 2024-04-26
AU2017281907B2 (en) 2021-10-21
BR112018076441A2 (pt) 2019-04-09
WO2017223474A1 (en) 2017-12-28
ZA201808099B (en) 2019-07-31
CA3025260A1 (en) 2017-12-28
US10899734B2 (en) 2021-01-26
RU2019101613A3 (enExample) 2020-12-03
IL263649A (en) 2019-01-31
JP7078555B2 (ja) 2022-05-31
MX383697B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
SA518400696B1 (ar) معدِّلات صغيرة الجزيء لإنزيمات بانتوثينات كيناز
Mahato et al. Pharmaceutical dosage forms and drug delivery: revised and expanded
ES2772133T3 (es) Compuestos heteroarilo como inhibidores de IRAK y sus usos
ES2689177T3 (es) Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
SA518400371B1 (ar) مشتقات سلفوناميد عطرية
SA515361151B1 (ar) مركبات أريل غير متجانسة واستخداماتها
UA128921C2 (uk) КОМБІНОВАНА ТЕРАПІЯ, ЩО ВКЛЮЧАЄ ІНГІБІТОР KRAS<sup>G12C</sup> ТА ОДИН АБО ДЕКІЛЬКА ДОДАТКОВИХ ФАРМАЦЕВТИЧНО АКТИВНИХ ЗАСОБІВ, ДЛЯ ЛІКУВАННЯ ВИДІВ РАКУ
UA121747C2 (uk) Фармацевтичні сполуки
CN102850324A (zh) 吲哚化合物
HUE030364T2 (hu) Glukagonreceptor modulátora
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
US20220251097A1 (en) Molecules and methods related to treatment of uncontrolled cellular proliferation
UA121104C2 (uk) Гетероциклічні сполуки і їх застосування
HK1211293A1 (en) Bruton's tyrosine kinase inhibitors
AU2014312919A1 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
SA517381743B1 (ar) مركبات مشتقة من5-[(بيبيرازين-1-يل)]-3-أوكسو-بروبيل]-إيميدازوليدين-2، 4-ديون بصفتها مثبطات adamts لمعالجة الفصال العظمي
CN106220623A (zh) 用于激酶调节的化合物和方法及其适应症
TW200524934A (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
TW201329078A (zh) 嘌呤酮衍生物鹽酸鹽
HUE034210T2 (hu) Neprilizininhibitorok
CN102271681A (zh) Cxcr7调节剂
EA021362B1 (ru) ПРОИЗВОДНЫЕ 2-БЕНЗИЛПИРИДАЗИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Мet КИНАЗЫ
HUE028495T2 (hu) Új piperidinvegyület vagy sói
PH12014502180B1 (en) Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
CN104177363A (zh) 双环杂环胺类Hedgehog信号通路抑制剂